Introduction
To date, over 100 different genotypes of the human papillomaviruses (HPV) have been fully characterized. Infection with HPV can present a wide variety of clinical manifestations of the skin and mucosa, most commonly as warts, either skin or genital (18) , although many HPV infections, especially those of the skin, are often without clinical symptoms (1, 2, 4) . The most important HPV-associated disease is undoubtedly cancer. Cervical cancer and many other anogenital cancers are caused by HPVinfections, and many other cancer forms have either been proven or are suspected to be linked to HPV (27) .
The papillomaviruses require proliferating basal layer cells and must access the basal cell layer of the epidermis or mucosa to establish infection. Hence, the transmission of HPV is believed to be facilitated by the presence of abraded or macerated epithelial surfaces (18) . All papillomavirus genes are transcribed in the epithelia, and the viral particles are assembled and released in the most superficial layers of the epithelium (22) . It has long been believed that papillomavirus cannot be spread to different body sites through blood, as papillomaviruses do not give rise to viremia. However, several recent studies have shown that HPV DNA can be found in circulating blood, including peripheral blood mononuclear cells (PBMCs), sera, plasma and arterial cord blood (3, 9, 21, 23, 24) . So far, most of these studies have only been conducted in female cancer patients, with relatively small sample sizes.
Only mucosal HPV types have been detected in blood, and no active viral replication has been found.
The presence of HPV-16 and HPV-18 E6 mRNA in peripheral blood of cervical cancer patients has also been suggested to provide an early biomarker that identifies patients who are at risk for developing metastases (24) .
In light of these findings, we wanted to establish if HPV DNA is present in the blood of healthy individuals. We thus examined DNA extracted PBMCs from 180 healthy male Red Cross blood donors and different blood cell fractions from one healthy male.
Materials and Methods

Healthy male Red Cross blood donors
Blood samples were collected from 180 healthy male blood donors, recruited through the Australian For the second blood collection 60 ml was taken, PBMCs were isolated with Ficoll blood separation, red blood cells lysed , and PBMCs were then treated with 5 ml of trypsin for 5 minutes. Thirty ml of serum (that also contains the platelets) was collected and PBMCs were separated into seven different Blood & Cell Culture DNA Midi Kit was used to extract DNA from each cell type fraction.
Forty ml of blood was collected at the third occasion and PBMCs were isolated with Ficoll blood separation as described above. After the Ficoll treatment, half of the PBMCs were treated with 5 ml of trypsin for 5 minutes before DNA was extracted using Qiagen Blood & Cell Culture DNA Midi Kit.
The other half of the PBMCs were DNA extracted with the same Qiagen Midi Kit (without previous trypsin treatment).
For the fourth blood collection 60 ml was collected and the PBMCs were isolated as described for the second blood collection, with the only exception that the PBMCs were not treated with trypsin. The
PBMCs were then separated into eight different fractions with MACS  MicroBeads as described for the second blood collection, with the exception that the dendritic cells this time were fractioned into mDCs and plasmacytoid dendritic cells (pDCs). The pDCs were isolated using the CD304 (BDCA-4/Neuropilin-1) MACS  MicroBead kit. DNA of each cell fractions was extracted using Qiagen Blood & Cell Culture DNA Midi kit (Qiagen).
To rule out contamination of HPV DNA from the skin surface in the blood samples, swab specimens were collected from four other skin sites when blood was collected at the second, third and fourth blood collection. The four swab samples were collected from; 1. the skin of the antecubital site before the blood was taken, 2. the antecubital site stripped with tape that was attached five times, then new tape was attached for another five times (sample taken before blood collection), 3. the needle after the blood had been collected and 4. the skin of the forehead. The tape-stripped method aimed to remove any possible HPV DNA shed on the skin surface. Pre-wetted cotton-tipped swabs (Q-TIPS, Tyco
Healthcare Group LP, Mansfield, MA, USA) were soaked in sterile saline solution (0.9% NaCl) and drawn back and forth five times over the skin, and the swab was then suspended in 1ml saline solution.
Samples were analysed directly after collection and then stored at -20°C.
HPV DNA detection and typing
The samples were tested with PCR for HPV DNA with the general primer-pair FAP59/FAP64 (12), using a previously described protocol, except for the MgCl 2 concentration, which was modified to 3. 
Results
Detection of HPV DNA in PBMCs from healthy blood donors
We found 8.3% ( which within the range to the entire sample set examined is similar to the blood donors (range 19 to 76 years of age; Table 1 ).
Isolation of HPV DNA in different blood cell fractions
From the four blood samples collected from the 44-year old healthy male, we found that only PBMCs that were not treated with trypsin were HPV positive ( Table 2 ).
The first blood sample was not trypsin-treated and B cells were separated from the rest of the PBMCs with magnetic bead sorting. Both the B cell fraction and the other PBMCs were found to be HPV DNA positive for a skin HPV type, HPV-FADI3.
Cells from the second blood collection were treated with trypsin before the PBMCs were separated into seven different fractions (B cells, myeloid dendritic cells, T cells, NK cells, macrophages and monocytes, neutrophils and flow-through). The serum and the seven cell fractions were all HPV DNA negative.
In the third blood sample, we found that the PBMCs that were treated with trypsin were HPV DNA negative, while those that were not trypsinised before DNA extraction were HPV DNA positive for HPV-FADI3.
The fourth blood sample was not treated with trypsin and after serum (containing platelets) and red All skin swabs from the antecubital site (before and after the tape-strip method) and the forehead were HPV DNA negative. The swab samples from the needles were also HPV DNA negative.
Discussion
Certain high-risk HPV types have been recognized as the causative agents of 99.7% of all cervical cancers (25) . High-risk HPV, in particular HPV-16 has been detected in anogenital cancers (other than cervical), and in esophageal, oropharyngeal and oral squamous cell carcinoma (6, 13, 14, 27) . Other studies have reported HPV findings in cancers that occur at sites where direct HPV infection is usually not seen, including colorectal, lung and breast cancer (5, 7, 16) . Detection of HPV in cancers like this raises the question how HPV got to the site of cancer. One possibility is that it was transported in blood, and HPV DNA has indeed been reported to be found in peripheral blood mononuclear cells (PBMCs), sera and plasma (3, 9) . We found 8.3% (15/180) of our healthy blood donors to be HPV positive. Half of the HPV types detected in the PBMCs were skin HPV types that are commonly found in asymptomatic infections of normal, healthy skin (1, 4) . The rest were high-risk HPV types that are associated with cancer development were detected in 1.7% (3/180) of the samples. HPV is estimated to cause 3-5% of all human cancers (19) and, although the numbers are small in this study, this HPV DNA prevalence in healthy males merits further investigation. While previous studies have suggested that HPV DNA in blood originated from cervical cancer cells (9, 23, 24) , this would not explain our findings since participants in our study were male blood donors. However, participants in this study were healthy blood donating men, although due to the anonymous collection of blood we cannot exclude the possibility that the healthy male blood donors had a type of cancer caused by HPV, like penile or oral squamous cell carcinoma (13, 14) .
HPV DNA was only detected in blood when we analysed PBMCs that had not been treated with trypsin. Therefore, HPV appears to be attached to the PBMCs by a cell surface protein. It has previously been shown that PV virions can bind to a wide range of cell types from different species (20) and our data suggest that HPV is attached to the cell surface of the PBMCs and is not taken up by the cell. α6 integrin receptors have been suggested to bind and mediate uptake of the virus particles into the cells (11) . T cells and platelets express α6 integrin receptors (26) , however the serum and T cell fractions in our study were HPV DNA negative. Our results showed a widespread distribution of different HPV types in various blood cell types, suggesting that the HPV virions tend to attach more to some types of PMBCs than others. We and others have shown that glycosaminoglycans are able to bind HPV with low affinity (10, 15) . Furthermore, to identify which specific receptors mediates the uptake of HPV into peripheral blood is important.
Our results provide evidence that HPV cannot only be spread through sexual contacts, skin abrasions or close contacts, but also via a new route where it enters the peripheral blood with the help of PBMCs.
According to our present state of knowledge, replication of HPV is strictly synchronized with the life cycle of mucosal or cutaneous epithelial cells (22) , however the presence of HPV DNA in blood, including high risk HPV types, suggests that further studies are needed to elucidate whether HPV virions can be transmitted through blood transfusion. Furthermore, the potential of blood being the vehicle for HPV to infect at other body organs has still yet to be determined. 
